Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 15:14:1132791.
doi: 10.3389/fpsyt.2023.1132791. eCollection 2023.

Prospective study on Maresin-1 and cytokine levels in medication-naïve adolescents with first-episode major depressive disorder

Affiliations

Prospective study on Maresin-1 and cytokine levels in medication-naïve adolescents with first-episode major depressive disorder

Tian Qiu et al. Front Psychiatry. .

Abstract

Background: Inflammation and immune activation may play a role in the pathological mechanism of Major Depressive Disorder (MDD). Evidence from cross-sectional and longitudinal studies of adolescents and adults has shown that MDD is associated with increased plasma pro-inflammatory cytokines (e.g., IL-1β, IL-6). It has been reported that Specialized Pro-resolving Mediators (SPMs) mediate inflammation resolution, and Maresin-1 can activate the process of inflammation and promote inflammation resolution by promoting macrophage phagocytosis. However, no clinical studies have been conducted to evaluate the relationship between the levels of Maresin-1 and cytokine and the severity of MDD symptomatology in adolescents.

Methods: 40 untreated adolescent patients with primary and moderate to severe MDD and 30 healthy participants as the healthy control (HC) group aged between 13 and 18 years old were enrolled. They received clinical and Hamilton Depression Rating Scale (HDRS-17) evaluation and then, blood samples were collected. Patients in the MDD group were re-evaluated for HDRS-17, and blood samples were taken after a six to eight-week fluoxetine treatment.

Results: The adolescent patients with MDD had lower serum levels of Maresin-1 and higher serum levels of interleukin 6 (IL-6) compared with the HC group. Fluoxetine treatment alleviated depressive symptoms in MDD adolescent patients, which was reflected by higher serum levels of Maresin-1 and IL-4 and lower HDRS-17 scores, serum levels of IL-6, and IL-1β. Moreover, the serum level of Maresin-1 was negatively correlated with the depression severity scores on the HDRS-17.

Conclusion: Adolescent patients with primary MDD had lower levels of Maresin-1 and higher levels of IL-6 compared with the HC group, implying that the peripheral level of pro-inflammatory cytokines may be elevated in MDD, resulting in the insufficiency of inflammation resolution. The Maresin-1 and IL-4 levels increased after anti-depressant treatment, whereas IL-6 and IL-1β levels decreased significantly. Moreover, Maresin-1 level negatively correlated with depression severity, suggesting that reduced levels of Maresin-1 promoted the progression of MDD.

Keywords: Maresin-1; adolescent; cytokines; major depressive disorder; medication-naïve.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The cytokine serum level and Maresin-1 serum level comparison between adolescents with MDD healthy Controls and adolescents with MDD at baseline. *p < 0 05; **p < 0 01. p-Value was calculated using the t-test was performed for statistical analysis.
Figure 2
Figure 2
Pre-MDD: before the fluoxetine treatment. Post-MDD: after the fluoxetine treatment. Values are presented as mean ± standard deviation for continuous variables, p-Value was calculated using the t-test *Statistically significant: p < 0.05.

Similar articles

Cited by

References

    1. GBD 2016 Disease and injury incidence and prevalence . Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. (2017) 390:1211–59. doi: 10.1016/S0140-6736(17)32154-2, PMID: - DOI - PMC - PubMed
    1. Kessler RC, Berglund P, DemLer O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. (2005) 62:593–602. doi: 10.1001/archpsyc.62.6.593, PMID: - DOI - PubMed
    1. Avenevoli S, Baio J, Bitsko RH, Blumberg SJ, Brody DJ, Crosby A, et al. . Mental health surveillance among children—United States, 2005–2011. (2013). MMWR supplements, 62:1–35. - PubMed
    1. Avenevoli S, Swendsen J, He JP, Burstein M, Merikangas KR. Major depression in the national comorbidity survey-adolescent supplement: prevalence, correlates, and treatment. J Am Acad Child Adolesc Psychiatry. (2015) 54:37–44.e2. doi: 10.1016/j.jaac.2014.10.010, PMID: - DOI - PMC - PubMed
    1. Cox G, Hetrick S. Psychosocial interventions for self-harm, suicidal ideation and suicide attempt in children and young people: what? How? Who? And where? Evid Based Ment Health. (2017) 20:35–40. doi: 10.1136/eb-2017-102667, PMID: - DOI - PMC - PubMed

LinkOut - more resources